Portage Biotech (PRTG) reported late Thursday "encouraging" efficacy data in a murine mesothelioma model with PORT-7 given as a single agent or in combination with anti-PD-1 antibody.
The data showed both single agent activity, and more than 90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma, it said.
"This is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor," Portage said, adding that it's making preparations to start a first-in-human trial.
The shares more than doubled in after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。